Buy Aehr Test Systems, Sell Cassava Sciences
Here's How Much $1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
Cassava Shares Rise After Incoming Chairman Gives Timeline for Alzheimer's Drug Study Read Out
Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
Why Cassava Sciences Stock Is Skyrocketing Today
Express News | Cassava Sciences Shares Are Trading Higher After the Company Announced Its First Phase 3 Trial Is Expected to Conclude by December and Its Second Phase 3 Trial Is Expected to Conclude by June 2025
Cassava Sciences Chairman Shares Insights in Open Letter
Express News | Cassava Sciences Shares up 3.2% Premarket; Data From Late-Stage Trial of Co's Alzheimer's Drug Is Expected in December
Express News | Cassava Sciences Executive Chairman Rick Barry Issues An Open Letter To "Shareholders, Employees, Principal Investigators, Patients And Their Loved Ones" On July 21, 2024
Express News | Cassava Sciences' Phase 3 Trial Expected To Conclude By December 2024 With 804 Patients; Second Trial With 1,125 Patients To End By June 2025; Successful Results Could Be Revolutionary
Express News | Cassava Sciences : Board Is 100% Committed to Completing Phase 3 Program, Releasing Results on Time
Express News | Cassava Sciences : Will Inform Cassava Community of Material News About Co and Clinical Trials
Express News | Cassava Sciences Inc: Second Phase 3 Trial Is Expected to Conclude by June 2025
Express News | Cassava Sciences Inc: First Phase 3 Trial Is Expected to Read Out by December 2024 - SEC Filing
Cassava Sciences Analyst Ratings
H.C. Wainwright Maintains Cassava Sciences(SAVA.US) With Hold Rating
H.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)
Sector Update: Health Care Stocks Advance Late Afternoon
No Data